Spots Global Cancer Trial Database for tace
Every month we try and update this database with for tace cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Trial of Transcatheter Arterial Chemoembolization (TACE) With Sorafenib for Locally Advanced Hepatocellular Carcinoma (HCC) | NCT01170104 | Hepatocellular ... | Sorafenib TACE (Transcath... | 18 Years - | Chung-Ang University | |
| Transarterial Chemoembolisation Plus Bevacizumab for Treatment of Hepatocellular Carcinoma | NCT00280007 | Hepatocellular ... | bevacizumab | 18 Years - 85 Years | Medical University of Vienna | |
| Combined Locoregional Treatment With Immunotherapy for Unresectable HCC. | NCT04220944 | Hepatic Carcino... | Sintilimab Microwave Ablat... TACE | 18 Years - 80 Years | Shanghai Zhongshan Hospital | |
| TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCC | NCT04992143 | BCLC Stage C He... | TACE Tilelizumab Sorafenib | 18 Years - | First Affiliated Hospital of Zhejiang University | |
| Parecoxib Versus Celecoxib Versus Oxycodone in Pain Control for Transcatheter Chemoembolization Procedure | NCT03059238 | Liver Cancer Pain Postoperat... | Celecoxib 200mg... parecoxib sodiu... controlled-rele... | 18 Years - 75 Years | Sun Yat-sen University | |
| Substudy: Interconnection of Arterial Tumor Feeders Through Tumor Sinusoid in HCC | NCT04641637 | Hepatocellular ... | TACE | 18 Years - | Chinese University of Hong Kong | |
| Safety and Efficacy of Arsenic Trioxide Contained in TACE in the Treatment of HCC | NCT02018757 | Carcinoma, Hepa... | TACE containing... TACE containing... | 18 Years - 75 Years | First Hospital of China Medical University | |
| Study of Apatinib Combined With TACE in Advance Hepatocellular Carcinoma | NCT03398122 | Hepatocellular ... | TACE Apatinib | 18 Years - 70 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC | NCT00576056 | Carcinoma, Hepa... | Sorafenib TACE | 18 Years - 100 Years | University of Pittsburgh | |
| A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma | NCT05320692 | Hepatocellular ... | TACE+Camrelizum... TACE | 18 Years - | Jiangsu HengRui Medicine Co., Ltd. | |
| SBRT Plus Lenvatinib and TACE for Advanced Primary HCC: A Phase 3 Trial (SEARCH) | NCT05718232 | Advanced Hepato... | Lenvatinib TACE SBRT | 18 Years - 75 Years | Sun Yat-sen University | |
| Hepatic Resection Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Complicated by Portal Vein Tumor Thrombosis | NCT01350206 | Hepatocellular ... | hepatic resecti... TACE | 18 Years - 75 Years | Sun Yat-sen University | |
| Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCC | NCT05056337 | Hepatocellular ... | Lenvatinib 4 MG... Toripalimab TACE | 18 Years - 75 Years | Shanghai Zhongshan Hospital | |
| Sorafenib and TACE as Adjuvant Therapy for MVI in HCC Patients After Radical Resection | NCT02537158 | Hepatocellular ... | Sorafenib TACE | 18 Years - 75 Years | ChineseAMS | |
| Treatment for Patients With Multiple Hepatocellular Carcinomas Based on the NDR Scoring System | NCT02525952 | Hepatocellular ... | Hepatectomy TACE | 18 Years - 70 Years | Eastern Hepatobiliary Surgery Hospital | |
| Lipiodol Deposition Using Endhole vs. Pressure-Modulated Delivery | NCT06204159 | Hepatocellular ... Neuroendocrine ... | TACE Catheters | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Role of (LMWH) in Prevention of Thromboembolic Complication After (TACE) in Hepatocellular Carcinoma. | NCT02715492 | HCC | LMWH TACE | 40 Years - 60 Years | Tanta University | |
| Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients | NCT02956772 | Primary Hepatoc... | TACE Arsenic trioxid... | 18 Years - 80 Years | Hunan Provincial People's Hospital | |
| Combination Chemoembolization and Stereotactic Body Radiation Therapy in Unresectable Hepatocellular Carcinoma | NCT02513199 | Hepatocellular ... | SBRT TACE | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma | NCT05717738 | Hepatocellular ... | TACE Lenvatinib Anti-PD-1 monoc... Bevacizumab Bio... Bevacizumab plu... apatinib plus c... Sorafenib Donafenib Regorafenib | 18 Years - | Tongji Hospital | |
| Trial of Transcatheter Arterial Chemoembolization (TACE) With Sorafenib for Locally Advanced Hepatocellular Carcinoma (HCC) | NCT01170104 | Hepatocellular ... | Sorafenib TACE (Transcath... | 18 Years - | Chung-Ang University | |
| Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma | NCT03572582 | Carcinoma, Hepa... Hepatic Carcino... Hepatocellular ... | Nivolumab TACE | 18 Years - | AIO-Studien-gGmbH | |
| Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC | NCT04157140 | Hepatocellular ... | Anlotinib TACE+RFA | 18 Years - 75 Years | Beijing Ditan Hospital | |
| Non-inferiority Study of Unresectable Hepatocelluar Carcinoma Receiving Stereotactic Radiotherapy Combined With Hepatic Arterial Chemoembolization Compared With Conversion Hepatectomy | NCT05057104 | Hepatocellular ... Conversion | 18 Years - 80 Years | Beijing 302 Hospital | ||
| TH-302 Plus Doxorubicin Delivered by Trans-Arterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma | NCT01721941 | Hepatocellular ... | Phase I Dose le... Phase I dose le... Phase I Dose le... Phase I Dose le... | 18 Years - | Scripps Clinic Cancer Center | |
| cTACE Plus Sintilimab for Unresectable Intermediate-stage HCC With Beyond Up-to-seven Criteria | NCT04842565 | Hepatocellular ... | Sintilimab TACE | 20 Years - 75 Years | Fudan University | |
| Liver Stiffness Measurement (LSM) in Predicting Progress of Liver Fibrosis After TACE for Hepatocellular Carcinoma | NCT03285867 | Hepatocellular ... Liver Failure | TACE | 18 Years - 80 Years | Nanfang Hospital, Southern Medical University | |
| TACE Associated to Systemic Bevacizumab for the Treatment of Refractory Liver Metastases From Colorectal Cancer | NCT03732235 | Liver Metastasi... | TACE+ systemic ... FOLFIRI+Bevaciz... TACE | 18 Years - | International Group of Endovascular Oncology | |
| A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC | NCT05319431 | Unresectable, N... | AK104 Lenvatinib TACE | 18 Years - 75 Years | Akeso | |
| Efficacy Study of TACE to Treat Hepatocellular Carcinoma After Operation | NCT02631499 | Carcinoma, Hepa... Neoplastic Cell... | TACE Epirubicin lipiodol | 18 Years - 75 Years | Fudan University | |
| Liver Stiffness Measurement (LSM) in Predicting Progress of Liver Fibrosis After TACE for Hepatocellular Carcinoma | NCT03285867 | Hepatocellular ... Liver Failure | TACE | 18 Years - 80 Years | Nanfang Hospital, Southern Medical University | |
| TACE Combined With Sintilimab Plus Bevacizumab Biosimilar in Hepatocellular Carcinoma (BCLC-C Stage ): a Prospective Single-arm Phase II Clinical Study | NCT04796025 | Hepatocellular ... | Sintilimab; Bev... | 18 Years - 69 Years | Sun Yat-sen University | |
| Tislelizumab in Combination With TACE in Advanced Hepatocellular Carcinoma | NCT04652492 | Hepatocellular ... | Tislelizumab in... | 18 Years - 70 Years | Zhongda Hospital | |
| TACE Combined With Bevacizumab in HCC (BCLC-B) Beyond Up-To-Seven Criteria | NCT05883176 | Hepatocellular ... | Bevacizumab Bio... | 18 Years - 70 Years | Sun Yat-sen University | |
| Transcatheter Arterial Chemoembolization With KMG Microsphere Treating Advance-stage Hepatocellular Carinomas (TACE-KMG) | NCT01393197 | Carcinoma, Hepa... | Therapeutic Che... | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Trial of Transcatheter Arterial Chemoembolization (TACE) With Sorafenib for Locally Advanced Hepatocellular Carcinoma (HCC) | NCT01170104 | Hepatocellular ... | Sorafenib TACE (Transcath... | 18 Years - | Chung-Ang University | |
| Radioembolization With Yittrium-90 for Intermediate and Advanced Hepatocellular Carcinoma | NCT02724436 | Hepatocellular ... Radioembolizati... | TACE radioembolizati... | 17 Years - 70 Years | Eastern Hepatobiliary Surgery Hospital | |
| Efficacy, Safety, and Treatment Patterns of Transcatheter Arterial Chemoembolization (TACE) Combined With Atezolizumab and Bevacizumab in Unresectable Hepatocellular Carcinoma: a Multicenter, Retrospective, Observational Real-world Study | NCT06024252 | HCC | TACE | 18 Years - | Zhongda Hospital | |
| A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC). | NCT00855218 | Carcinoma, Hepa... | Sorafenib (Nexa... Placebo | 18 Years - | Bayer | |
| Transarterial Chemoembolization Plus Hypofractionnated Radiotherapy vs. Surgery in Locally Advanced Hepatocellular Carcinoma: an IPTW Comparison | NCT04823715 | Non-metastatic ... | TACE + hypofrac... Surgical resect... | 18 Years - | Hospices Civils de Lyon | |
| Evaluation of Cytokine-induced Killer (CIK) Cells as Therapy or Adjuvant Treatment for Advanced HCC | NCT02568748 | Liver Cancer | CIK TACE | - | Tanta University | |
| Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients | NCT02956772 | Primary Hepatoc... | TACE Arsenic trioxid... | 18 Years - 80 Years | Hunan Provincial People's Hospital | |
| Sequential TACE and SBRT Followed by ImmunoTherapy for Downstaging HCC for Hepatectomy | NCT03817736 | HCC | TACE SBRT Immune Checkpoi... | 18 Years - 75 Years | The University of Hong Kong | |
| Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC | NCT04157140 | Hepatocellular ... | Anlotinib TACE+RFA | 18 Years - 75 Years | Beijing Ditan Hospital | |
| Radiofrequency-assisted Liver Resection in Intractable Liver Cancer | NCT04413526 | Liver Cancer | radiofrequency TACE TACE+radiofrequ... | 18 Years - 90 Years | Hepatopancreatobiliary Surgery Institute of Gansu Province | |
| The Role of Low Molecular Weight Heparins in Hepatocellular Carcinoma | NCT00827554 | Hepatocellular ... | LMWH TACE | 18 Years - 75 Years | Eastern Hepatobiliary Surgery Hospital | |
| Anti-recurrence Treatment of Postresection on HCC Patients With MVI Presence and Over-expression of ASPH | NCT02587884 | Hepatocellular ... | TACE | 18 Years - 70 Years | Eastern Hepatobiliary Surgery Hospital | |
| SNMC (Stronger Neo-Minophagen C ) for Acute Hepatitis Post Transarterial Chemoembolization Therapy | NCT04015245 | Hepatocellular ... | Stronger Neo-Mi... | 18 Years - | Chimei Medical Center | |
| Efficacy of Sequential TACE and PVE on the Resectability of Hepatitis B Related HCC | NCT00834158 | Hepatocellular ... | TACE PVE | 20 Years - 65 Years | Eastern Hepatobiliary Surgery Hospital | |
| Parecoxib Versus Celecoxib Versus Oxycodone in Pain Control for Transcatheter Chemoembolization Procedure | NCT03059238 | Liver Cancer Pain Postoperat... | Celecoxib 200mg... parecoxib sodiu... controlled-rele... | 18 Years - 75 Years | Sun Yat-sen University | |
| TACE Combined With Sintilimab Plus Bevacizumab Biosimilar in Patients With Advanced Hepatocellular Carcinoma (TASK-02) | NCT04954794 | Hepatocellular ... | Sintilimab TACE | 18 Years - | Fudan University | |
| Study of TACE Combined With Lenvatinib to Prevent Postoperative Recurrence in Patients With MVI Positive HCC | NCT04911959 | Hepatocellular ... Lenvatinib | Lenvatinib TACE | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| TACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma | NCT04297280 | Hepatocellular ... | Sintilimab TACE | 18 Years - | Fudan University | |
| TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (Prolong) | NCT04560751 | Carcinoma, Hepa... | Lenvatinib TACE | 18 Years - 75 Years | Zhejiang Cancer Hospital | |
| A Novel Immunotherapy PD-1 Antiboty to Suppress Recurrence of HCC Combined With PVTT After Hepatic Resection | NCT03914352 | Hepatocellular ... | PD-1 antibody TACE | 18 Years - 75 Years | Cancer Hospital of Guangxi Medical University | |
| The Role of Low Molecular Weight Heparins in Hepatocellular Carcinoma | NCT00827554 | Hepatocellular ... | LMWH TACE | 18 Years - 75 Years | Eastern Hepatobiliary Surgery Hospital | |
| Trans-catheter Chemo-embolization Combined With rAd-p53 Gene Injection in Treatment of Advanced Hepatocellular Carcinoma | NCT02418988 | Advanced Adult ... | TACE plus rAd-p... TACE | 18 Years - 80 Years | Shenzhen SiBiono GeneTech Co.,Ltd | |
| Safety and Efficacy of Arsenic Trioxide Contained in TACE in the Treatment of HCC | NCT02018757 | Carcinoma, Hepa... | TACE containing... TACE containing... | 18 Years - 75 Years | First Hospital of China Medical University | |
| TACE With Lenvatinib Versus Lenvatinib Alone in in First-line Treatment of Advanced HCC | NCT03905967 | Advanced Hepato... | TACE Lenvatinib | 18 Years - 75 Years | Sun Yat-sen University | |
| TACE Plus Recombinant Human Adenovirus for Hepatocellular Carcinoma | NCT01869088 | Hepatocellular ... | Recombinant Hum... Transartery Che... | 18 Years - 70 Years | Sun Yat-sen University | |
| Transcatheter Arterial Chemoembolization With KMG Microsphere Treating Advance-stage Hepatocellular Carinomas | NCT01393093 | Carcinoma, Hepa... | Therapeutic Che... | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) Versus Adjuvant Transarterial Chemoembolization (TACE) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial. | NCT03192644 | Hepatocellular ... | TAI TACE epidoxorubicin ... mFOLFOX6 (oxali... | 18 Years - 75 Years | Sun Yat-sen University | |
| TACE Combined With Sintilimab Plus Bevacizumab Biosimilar in Patients With Advanced Hepatocellular Carcinoma (TASK-02) | NCT04954794 | Hepatocellular ... | Sintilimab TACE | 18 Years - | Fudan University | |
| Perioperative Therapy for Hepatocellular Carcinoma | NCT04653389 | Hepatocellular ... | Sintilimab Inje... TACE Radiotherapy | 18 Years - 75 Years | Zhejiang University | |
| Anti-angiogenic Targeted Drugs Plus Rg3 to Improve the Efficacy of TACE for Unresectable Hepatocellular Carcinoma | NCT04523467 | Hepatocellular ... | Anti-angiogenic... Ginsenoside Rg3 TACE | 18 Years - 75 Years | Eastern Hepatobiliary Surgery Hospital | |
| TACE With Dicycloplatin(TP21) in Unresectable HCC | NCT05472896 | Hepatocellular ... | cTACE Dicycloplatin (... Epirubicin | 18 Years - | Zhongda Hospital | |
| TACE Combined With Lenvatinib Versus TACE Sequential Lenvatinib in the Treatment of Intermediate/Advanced Liver Cancer | NCT05220020 | Hepatocellular ... | TACE(Transcathe... Lenvatinib | 18 Years - 75 Years | Sun Yat-sen University | |
| Postoperative TACE(Transhepatic Arterial Chemotherapy And Embolization) for Patients With Hepatocellular Carcinoma | NCT02109146 | Hepatocellular ... Transcatheter A... | Prophylactic Tr... Observation | 18 Years - 80 Years | Zhejiang University | |
| A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma | NCT06371157 | Hepatocellular ... | AK104 Lenvatinib TACE Placebo for AK1... Placebo for Len... | 18 Years - 75 Years | Akeso | |
| TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma | NCT04988945 | HCC | TACE SBRT Durvalumab Tremelimumab | 18 Years - | The University of Hong Kong | |
| Prospective Study to Evaluate Safety of Deb-TACE With 100µ Beads in Patients With Non Resectable HCC | NCT02670122 | Hepatocellular ... | DEB-TACE | 18 Years - 90 Years | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | |
| A Trial on SBRT After Incomplete TAE or TACE Versus Exclusive TAE or TACE For Treatment of Inoperable HCC | NCT02323360 | Hepatocellular ... | SBRT TACE | 18 Years - 95 Years | Istituto Clinico Humanitas | |
| Selective Internal Radiotherapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Cholangiocellular Carcinoma (CCC). | NCT01798147 | Intrahepatic Ch... | DEB TACE SIRT | 18 Years - | Johannes Gutenberg University Mainz | |
| Acupoint Electric Stimulation Combined With Tropisetron in Preventing and Treating Nausea and Vomiting After TACE | NCT01895010 | Nausea Vomiting Metastatic Live... | acupoint electr... tropisetron | 18 Years - | Fudan University | |
| Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma | NCT01833299 | Hepatocellular ... Face Cancer | TACE-Sorafenib ... TACE | 18 Years - 75 Years | Sun Yat-sen University | |
| Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients | NCT02956772 | Primary Hepatoc... | TACE Arsenic trioxid... | 18 Years - 80 Years | Hunan Provincial People's Hospital | |
| TACE and Adefovir Compared With Transarterial Chemoembolization (TACE) Alone for Hepatitis B Virus (HBV)-Related Unresectable Hepatocellular Carcinoma (HCC) | NCT00960518 | Hepatitis B Vir... Hepatocellular ... | adefovir TACE | 20 Years - 75 Years | Tongji University | |
| Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012) | NCT04246177 | Carcinoma, Hepa... | Lenvatinib Pembrolizumab Oral Placebo IV Placebo TACE | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection | NCT04981665 | Hepatocellular ... Adjuvant Therap... | Tislelizumab TACE | 18 Years - | Zhejiang University | |
| TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC | NCT05332821 | Hepatocellular ... | PD-1/PD-L1 inhi... TACE | 18 Years - | Zhongda Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
